Key takeaways

  • The FDA said Summit's ivonescimab didn't show a significant survival benefit.
  • Summit Therapeutics said Sunday that the Food and Drug Administration didn't approve a China-developed drug to treat lung cancer, citing insufficient evidence that it extended patients' lives.
  • The news could hit shares of Summit Therapeutics and big investor AstraZeneca.

The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.

See the latest quote, chart and news for SMMT.

Read the full story at investors.com ↗